Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of SPH6516 Tablets in Subjects With Advanced Solid Tumors.

NCT06266923 is registered in ClinicalTrials.gov with Shanghai Pharmaceuticals Holding Co., Ltd as lead sponsor.

NCT NCT06266923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06266923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of SPH6516 Tablets in Subjects With Advanced Solid Tumors.
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
January 20, 2022
Completion date
November 1, 2023
Enrollment
16 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor